Selvita SA

Chart & Performance

D1W1MN

No data to show

P/E

—

P/S

1.58

EPS

—

Div Yield, %

—

Shrs. gr., 5y

28.39%

Rev. gr., 5y

62.22%

Revenues

342m

-1.43%

Net income

-6m

CFO

64m

-18.88%

Profile

Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. The company offers drug discovery services in the areas of assay development and screening, medicinal and synthetic chemistry, computer-aided drug design/ artificial intelligence, structural biology, in vitro/ In Vivo pharmacology, ADME/DMPK and analytical testing. It also provides pharma services in the field of drug testing and bioanalytical analysis, including development and optimization, validation and transfer, stability studies, quality control, and regulatory aspects support services. In addition, the company offers research and development services in the areas of process research, laboratory scale custom synthesis of NCEs, industrial chemistry, and synthesis of isotopically labelled compounds, as well as other services for the agrochemical industry. Further, it provides bio-data science and advanced software services to data-driven life science and healthcare organizations. Selvita S.A. was founded in 2007 and is headquartered in Krakow, Poland.

URL

https://selvita.com/

IPO date

Oct 16, 2019

Employees

847

Domiciled in

Incorporated in

Valuation

Order:

Title PLN in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title PLN in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	342,007 -1.43%	346,957 -14.85%	407,462 31.05%
Cost of revenue	74,190	71,158	75,796
Unusual Expense (Income)
NOPBT	267,817	275,799	331,666
NOPBT Margin	78.31%	79.49%	81.40%
Operating Taxes	(4,356)	(2,675)	7,599
Tax Rate			2.29%
NOPAT	272,173	278,474	324,067
Net income	(6,098) -108.73%	69,878 130.55%	30,309 103.43%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current	142,713	46,893	41,464
Long-term debt	175,324	270,032	258,615
Deferred revenue	34,708	33,011	11,020
Other long-term liabilities	810	989	239
Net debt	295,525	200,647	225,829
Cash flow
Cash from operating activities	64,069	78,980	75,430
CAPEX	(18,710)	(73,934)	(101,586)
Cash from investing activities	(36,873)	(65,213)	(79,789)
Cash from financing activities	(57,342)	(30,968)	(5,672)
FCF	266,935	222,751	191,905
Balance
Cash	22,512	52,965	76,175
Long term investments		63,313	(1,925)
Excess cash	5,412	98,930	53,877
Stockholders' equity	147,286	240,623	186,713
Invested Capital	570,520	486,886	441,015
ROIC	51.48%	60.02%	88.26%
ROCE	46.24%	46.79%	66.17%
EV
Common stock shares outstanding	18,355	18,355	18,355
Price
Market cap
EV
EBITDA	320,916	321,251	368,494
EV/EBITDA
Interest	12,655	11,826	4,196
Interest/NOPBT	4.73%	4.29%	1.27%